Novel MYBPC3 Mutations in Indian Population with Cardiomyopathies

Deepa Selvi Rani¹, Apoorva Kasala¹, Perundurai S Dhandapani², Uthirlingam Muthusami³, Sreejith Kunnoth³, Andiappan Rathinavel⁴, Dharma Rakshak Ayapati⁵, Kumarasamy Thangaraj⁵,¹

¹Department of Population and Medical Genomics, CSIR-Centre for Cellular and Molecular Biology, Hyderabad, Telangana, India; ²Department of Cardiovascular Biology and Medicine, Institute for Stem Cell Science and Regenerative Medicine, Bangalore, Karnataka, India; ³Department of Advanced Zoology and Biotechnology, Loyola College, Chennai, Tamil Nadu, India; ⁴Department of Cardiology, Government Rajaji Hospital, Madurai, Tamil Nadu, India; ⁵Department of Cardiology, Nizam’s Institute of Medical Sciences, Hyderabad, Telangana, India; ⁶DBT-Centre for DNA Fingerprinting and Diagnostics, Hyderabad, Telangana, India

Correspondence: Deepa Selvi Rani; Kumarasamy Thangaraj, CSIR-Centre for Cellular and Molecular Biology, Uppal Road, Hyderabad, 500 007, India, Tel +91-40-271926, Email deepa@ccmb.res.in; thangs@ccmb.res.in

Background: Mutations in Myosin Binding Protein C (MYBPC3) are one of the most frequent causes of cardiomyopathies in the world, but not much data are available in India.

Methods: We carried out targeted direct sequencing of MYBPC3 in 115 hypertrophic (HCM) and 127 dilated (DCM) cardiomyopathy patients against 197 ethnically matched healthy controls from India.

Results: We detected 34 single nucleotide variations in MYBPC3, of which 19 were novel. We found a splice site mutation [(IVS6+2T) T>G] and 16 missense mutations in Indian cardiomyopathies [5 in HCM; E258K, T262S, H287L, R408M, V483A; 4 in DCM; T146N, V321L, A392T, G522E, A626V] in MYBPC3 were altering the evolutionarily conserved native amino acids, accounted for 8.7% and 6.3% in HCM and DCM, respectively. The bioinformatic tools predicted that those 7 missense mutations were pathogenic. Moreover, the cosegregation of those 7 mutations in families further confirmed their pathogenicity. Remarkably, we also identified compound mutations within the MYBPC3 gene of 6 cardiomyopathy patients (5%) with more severe disease phenotype; of which, 3 were HCM (2.6%) [(1. K244K + E258K + (IVS6+2T) T>G); (2. L104M + G522E + A626V)]; and 3 were DCM (2.4%) [(1. 5’UTR + A392T; 2. V158M+G522E; and 3.V158M + T262T + A626V).

Conclusion: The present comprehensive study on MYBPC3 has revealed both single and compound mutations in MYBPC3 and their association with disease in Indian Population with Cardiomyopathies. Our findings may perhaps help in initiating diagnostic strategies and eventually recognizing the targets for therapeutic interventions.

Keywords: MYBPC3, cardiomyopathy, sarcomere genes, HCM, DCM

Introduction
Cardiac Myosin Binding Protein C (MyBP-C_OMIM-600958), one of the thick filaments exhibited across the C zone of A-bands of sarcomeres, binds β-myosin (β-MYH7_OMIM-160710) in thick filaments and titin (TTN_OMIM-188840) in elastic filaments.¹,² It serves as a control that limits cross-bridge interactions between myosin and actin.³,⁴ Phosphorylation of MYBPC3 modulates contraction and is believed to play both structural and regulatory functions. A total of 3 isoforms of MyBP-C (a cardiac and two skeletal) have been reported, all 3 share a conserved region composed of 7 IgI (immunoglobulin) and 3 FnIII (fibronectin type III) domains.⁵ The cardiac isoform cMyBP-C contains a unique IgI domain (C0) at the N-terminus and four distinctive phosphorylation sites and an exclusive proline-rich 25 residue insertion at the C5 domain.⁵,⁶ Cardiomyopathy (CM), a heart muscle disease, is classified by its morphological features leading to subtypes called hypertrophic (HCM), dilated (DCM), left ventricular noncompaction (LVNC), restrictive (RCM), and arrhythmogenic right ventricular cardiomyopathy (ARVD/C).⁷,⁸ The former two (HCM and...
DCM) are the most frequent forms of cardiomyopathies, usually affecting the cardiac wall thickness, chamber size and ultimately pumping efficiency. Describing features of HCM include a hypertrophied/thickened left ventricle with weakened diastolic relaxation, myocyte disarray, and replacement fibrosis, with an estimated prevalence of 1 in 500. HCM is known as a “disease of the sarcomere”. Sarcomere consists of thick filaments of myosin and thin filaments of actin, tropomyosin, troponin complex, along with the assembly proteins cardiac myosin binding protein C and titin. To date, hundreds of mutations in sarcomere genes have been reported to cause cardiomyopathies, most of the mutations (~75%) were found in HCM and a few mutations (~10–16%) were in hereditary DCM. Mutations were predominantly reported in two sarcomere genes: β-Myosin heavy chain (MYH7) and Myosin binding protein C (MYBPC3). Defining characteristics of DCM are a left ventricular dilatation, myocardial fibrosis, and myocyte disease, which affect systolic function with an estimated prevalence of 1 in 2500. Currently, more than 40 genes, TTN, LMNA, DES, RBM20, etc., along with sarcomere genes were reported to cause familial DCM. The essence of mutation screening in disease genetics mostly relayed on the interpretation of genotype and phenotype correlation. Sometimes the factors that govern the variable phenotypic expressions are largely due to unknown factors like epigenetics, environment, lifestyle, etc., which may also possibly implicate a significant role in disease phenotypes. Mutations in myosin binding protein C (MYBPC3) gene, one of the most frequent causes of cardiomyopathies, studied extensively in various other populations but not much studied in the Indian population with cardiomyopathies. Therefore, here, we performed a targeted screening of the MYBPC3 gene in 242 cardiomyopathy patients against 197 controls (ethnically matched healthy individuals).

Materials and Methods
Study Population and Ethical Approval
The Institutional Ethical Committees (IECs) of CSIR-Centre for Cellular and Molecular Biology (CCMB) and other two participating hospitals [(1) Government Rajaji Hospital (GH), Madurai, India, and (2) Nizam’s Institute of Medical Sciences (NIMS), Hyderabad, India] have approved the study (Table 1). We obtained informed written consent from all the participated individuals before sample collection. We then collected ~5.0 mL of blood samples from each of the 242 patients consisting of 115 HCM, and 127 DCM along with 197 ethnically matched controls (who are healthy individuals without heart problems) (Table 1). To get permission to research human subjects the required guidelines and regulations were followed according to the principles outlined in the Declaration of Helsinki, the World Medical Association.

Genomic DNA
DNA was isolated from the peripheral blood of all cardiomyopathy patients and normal healthy controls using a standard protocol as follows. To the peripheral blood (5.0mL), we added 15mL of erythrocyte lysis buffer [containing 10mM Tris at pH 8.0, 320mM Sucrose, 5mM MgCl2, and 1% Triton X-100; Sigma Chemical Company, St. Louis, MO] for 5 minutes to lysis the erythrocytes. Leucocytes were pelleted by spinning for 5 minutes at 500g in a centrifuge. Leucocytes were lysed using 8mL of leucocyte lysis buffer (400mM Tris, 60mM EDTA, 150mM NaCl, and 1% SDS; Sigma Chemical Company). To this lysate, 2.0mL of 5M sodium perchlorate (E. Merck, Darmstadt, Germany) was added and mixed thoroughly for 2–3 min. DNA was precipitated using isopropanol, after extracting once with phenol:chloroform (1:1) and then with chloroform. DNA was washed 2 times with 70% ethanol, and the pellet was dissolved in the TE (10mM Tris at pH 8.0 and 1mM EDTA) buffer.

Polymerase Chain Reaction (PCR) and Sequence Analysis
The targeted primer sequences for PCR (Supplement Table S1) covering the exons, exon-intron boundaries of MYBPC3 were designed and synthesized using an ABI 392 oligo synthesizer (Perkin–Elmer, Foster City, CA). Using 50ng of genomic DNA as a template, Polymerase Chain Reactions (PCR) were carried out using 5pM of both forward and reverse primers (Supplementary Table S1), 200mM dNTPs, 10X PCR buffer containing 1.5mM MgCl2, and 1U of AmpliTaq Gold (Perkin–Elmer). Amplifications were carried out in a thermal cycler (MJ Research, Waltham, MA, USA) using the following cycling conditions: 94°C for 5 min, 35 cycles at 94°C for 1 min, 55–60°C for
1 min, 72°C for 1 min, followed by a final extension at 72°C for 10 min. Resulted PCR products (amplicons) were checked using 2% agarose gel electrophoresis. The PCR products were then purified using ExoSAP-IT enzyme (USB Corporation, USA) and subjected to cycle sequencing reaction in GeneAmp 9700 thermal cycler using Big Dye Terminator ready reaction cycle sequencing kit (Applied Biosystems, Foster City, USA). The cycle sequencing products were precipitated with ethanol, dried and dissolved in Hi-Di formamide, and bi-directional sequencing was performed in an ABI 3730XL automated DNA analyzer (Applied Biosystems, Foster City, USA). The MYBPC3 gene sequences obtained were noted and aligned with the Reference MYBPC3 gene sequences using Sequence Analyzer and Auto Assembler tools. We followed the American College of Medical Genetics and Genomics (ACMG) guidance for the interpretation of sequence variants.

All the mismatched nucleotide sequences were carefully noted and compared against 197 healthy control sequences to detect their significance. We used two bioinformatics tools, Polyphen-2 (Polymorphism phenotyping 2) and SIFT (Sorting intolerant from tolerant), to predict the possible pathogenic effects of missense mutations.

**Results**

In the present study, we identified 34 genetic variants in MYBPC3 gene (Table 2), of which 19 were novel (https://www.ncbi.nlm.nih.gov/SNP/snp_viewTable.cgi?handle=THANGARAJ_DEEPA_CCMB). We found a splice site mutation [(IVS6+2T) T>G] and 16 were missense mutations [5 in HCM (E258K, T262S, H287L, R408M, V483A), 4 in DCM (T146N, V321L, A392T, E393K) and 7 in both HCM and DCM (L104M, V158M, S236G, R272C, T290A, G522E, A626V)], but all those 16 mutations were absent in 197 controls (Figure 1A and B, Supplementary Figure S1; Table 2). We found 7 out of 16 heterozygous missense mutations in MYBPC3 [V158M, E258K, R272C, A392T, V483A, G522E, and A626V in MYBPC3 (Figure 1C and Table 3)] were altering the native evolutionarily conserved amino acids (Figure 1D). The Polyphen-2 or SIFT bioinformatics tools predicted that those 7 missense mutations were pathogenic (Table 2). The co-segregation of those 7 missense mutations in families also confirmed their pathogenicity, accounting for
Table 2 Comparing the Allele Frequencies of Detected Mutations in the MYBPC3 Gene of Indian Population vs Other Populations

<table>
<thead>
<tr>
<th>Position</th>
<th>Location</th>
<th>Change</th>
<th>PolyPhen-2</th>
<th>SIFT</th>
<th>Predictions</th>
<th>AA</th>
<th>Mean ASN-</th>
<th>EUR</th>
<th>Mean ASN-</th>
<th>IN_AF</th>
<th>EUR_AF</th>
<th>IN_AF</th>
<th>EUR_AF</th>
<th>Mean India</th>
<th>Mean EUR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exon 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exon 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exon 3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exon 4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exon 5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exon 6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exon 7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exon 8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exon 9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Legend:**
- **Exon:** Position in the gene.
- **Position:** Position in the coding sequence.
- **Major>Minor Allele:** The major and minor allele at the specified position.
- **Location:** Region of the gene.
- **SNP Reference:** Reference SNP ID.
- **AA Change:** Amino acid change.
- **PolyPhen-2:** Predicts the impact of the amino acid change.
- **SIFT:** Predicts the impact of the amino acid change.
- **Predictions:** Classification of the mutation.
- **IN_AF:** Allele frequency in the Indian population.
- **EUR_AF:** Allele frequency in the European population.
- **Mean ASC:** Mean amino acid shock.
<table>
<thead>
<tr>
<th>No.</th>
<th>Chromosome Position</th>
<th>SNP Reference</th>
<th>Exon Region</th>
<th>Genomic Location</th>
<th>Mutation Type</th>
<th>Gene</th>
<th>rsID</th>
<th>Consequence</th>
<th>Pathogenicity</th>
<th>Minor Allele Frequency</th>
<th>Major Allele Frequency</th>
<th>Risk Factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>27</td>
<td>1,147,365,060</td>
<td>g.10194</td>
<td>Exon 12</td>
<td>Novel-ss322063388</td>
<td>E402E</td>
<td>-</td>
<td>-</td>
<td>0</td>
<td>0.51</td>
<td>1.13</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>28</td>
<td>1,147,365,043</td>
<td>g.10211</td>
<td>Exon 12</td>
<td>Novel-ss322063387</td>
<td>R408H</td>
<td>Possibly Damaging</td>
<td>Damaging</td>
<td>Pathogenic</td>
<td>0</td>
<td>0.25</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>29</td>
<td>1,147,365,014</td>
<td>g.10240</td>
<td>Intron 12</td>
<td>rs1517007B</td>
<td>-</td>
<td>Polymorphic</td>
<td>0</td>
<td>0.28</td>
<td>0.09</td>
<td>0.06</td>
<td>0.03</td>
<td>0.1</td>
</tr>
<tr>
<td>30</td>
<td>1,147,364,392</td>
<td>g.10867</td>
<td>Exon 14</td>
<td>Novel-ss322063386</td>
<td>A482A</td>
<td>-</td>
<td>-</td>
<td>0</td>
<td>0.51</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>31</td>
<td>1,147,364,387</td>
<td>g.10867</td>
<td>Exon 14</td>
<td>Novel-ss322063385</td>
<td>V483A</td>
<td>Probably Damaging</td>
<td>Damaging</td>
<td>Pathogenic</td>
<td>0</td>
<td>0.25</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>32</td>
<td>1,147,364,185</td>
<td>g.11069</td>
<td>Exon 15</td>
<td>Novel-ss322063384</td>
<td>G522E</td>
<td>Probably Damaging</td>
<td>Damaging</td>
<td>Pathogenic</td>
<td>0</td>
<td>0.76</td>
<td>0.85</td>
<td>0</td>
</tr>
<tr>
<td>33</td>
<td>1,147,363,335</td>
<td>g.11719</td>
<td>Intron 16</td>
<td>Novel-ss213754466</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0</td>
<td>0.85</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>34</td>
<td>1,147,362,650</td>
<td>g.12548</td>
<td>Exon 20</td>
<td>Reported</td>
<td>A626V</td>
<td>Probably Damaging</td>
<td>Damaging</td>
<td>Pathogenic</td>
<td>0</td>
<td>1.27</td>
<td>0.85</td>
<td>0</td>
</tr>
</tbody>
</table>


**Abbreviations:** SNP, single nucleotide polymorphism; AA, amino acids; rs#, reference SNP number; PolyPhen-2, Phenotyping v2; SIFT, sorting intolerant from tolerant; CON, controls; HCM, hypertrophic cardiomyopathy; DCM, dilated cardiomyopathy; IN_AF, Allele frequency of Indian Ancestry; ASN_AF, Allele frequency of Asian Ancestry; AFR_AF, Allele frequency of African Ancestry; AMR_AF, Allele frequency of American Ancestry; EUR_AF, Allele frequency of European Ancestry.
8.7% and 6.3% in HCM and DCM, respectively. Interestingly, in the present study, 6 patients [3 HCM and 3 DCM (Table 4)] with more severe disease phenotypes have shown compound mutations in the **MYBPC3** gene. They were as follows; one was a 51-year-old HCM patient, who carried allelic heterogeneity by possessing three heterozygous mutations in the **MYBPC3** gene; [a splice site mutation (IVS6+2T) T>G, a missense mutation E258K, and a silent mutation K244K (Figure 1C)]. Another was a 53-year-old HCM patient with three missense mutations; L104M, G522E, and A626V. The third was a 49-year-old HCM patient, who possessed two missense mutations, G522E, A626V, and a silent mutation P186P. The following are the 3 dilated cardiomyopathy patients with more than one mutation in the **MYBPC3** gene. The 1st DCM patient carried a 5'UTR mutation and a missense mutation A392T. The 2nd DCM patient carried 2 missense mutations: V158M and G522E. The 3rd DCM patient possessed 3 missense mutations: V158M, T262T and A626V (Figure 1 and Table 3). In addition, we too detected 10 silent mutations exclusively in cardiomyopathy patients [3 in HCM (P186P, K24K, and A482A), 5 in DCM; A58A, T146T, P150P, G291G, D303D, 2 in both HCM and DCM; T262T and E402E], with unknown implication (Figure S1; Table 2).

**Discussion**

One of the interesting outcomes of the present study was the identification of compound variations within the **MYBPC3** gene of 6 cardiomyopathy patients with more severe disease presentation. Of which, 3 were HCM [(1. K244K + E258K + (IVS6+2T) T>G), (2. L104M + G522E + A626V) and (3. P186P + G522E + A626V)]; and 3 were DCM [(1. 5'UTR +
<table>
<thead>
<tr>
<th>S: NO</th>
<th>Chromosome Position</th>
<th>Position</th>
<th>Major&gt;Minor Allele</th>
<th>Location</th>
<th>SNP Reference</th>
<th>AA change</th>
<th>PolyPhen-2 SIFT</th>
<th>SIFT CON 197</th>
<th>HCM 115</th>
<th>DCM 127</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1,147,371,608</td>
<td>g.3656</td>
<td>G&gt;A</td>
<td>Exon 4</td>
<td>rs3729986</td>
<td>V158M</td>
<td>Possibly Damaging</td>
<td>Damaging</td>
<td>-</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>1,147,369,975</td>
<td>g.5279</td>
<td>G&gt;A</td>
<td>Exon 6</td>
<td>CM981322</td>
<td>E258K</td>
<td>Possibly Damaging</td>
<td>Damaging</td>
<td>-</td>
<td>2</td>
</tr>
<tr>
<td>3</td>
<td>1,147,369,415</td>
<td>g.5839</td>
<td>A&gt;T</td>
<td>Exon 7</td>
<td>rs397516075</td>
<td>R272C</td>
<td>Probably Damaging</td>
<td>Damaging</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>4</td>
<td>1,147,365,092</td>
<td>g.10162</td>
<td>G&gt;A</td>
<td>Exon 12</td>
<td>Novel-ss6322063390</td>
<td>A392T</td>
<td>Probably Damaging</td>
<td>Damaging</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>5</td>
<td>1,147,364,387</td>
<td>g.10867</td>
<td>T&gt;C</td>
<td>Exon 14</td>
<td>Novel-ss6322063385</td>
<td>V483A</td>
<td>Probably Damaging</td>
<td>Damaging</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>6</td>
<td>1,147,364,185</td>
<td>g.11069</td>
<td>G&gt;A</td>
<td>Exon 15</td>
<td>Novel-ss6322063384</td>
<td>G522E</td>
<td>Probably Damaging</td>
<td>Damaging</td>
<td>-</td>
<td>2</td>
</tr>
<tr>
<td>7</td>
<td>1,147,362,650</td>
<td>g.12548</td>
<td>C&gt;T</td>
<td>Exon 20</td>
<td>rs1352376969</td>
<td>A626V</td>
<td>Probably Damaging</td>
<td>Damaging</td>
<td>-</td>
<td>2</td>
</tr>
</tbody>
</table>

| Total |                      |          |                    |          |               |           |                 |             | 10/115=8.7% | 8/127=6.3% |

**Abbreviations:** SNP, single nucleotide polymorphism; AA, amino acids; rs#.No, reference SNP number; PolyPhen-2, Phenotyping v2; SIFT, sorting intolerant from tolerant; CON, controls; HCM, hypertrophic cardiomyopathy; DCM, dilated cardiomyopathy.
A392T, (2. V158M+G522E), and (3. V158M + T262T + A626V)] (Table 2 and Figure 1), accounting for 2.6% and 2.4% in Indian HCM and DCM patients, respectively. Further analysis of family members of all 6 patients with compound variations has demonstrated the segregation of those variations along with the disease. When we extracted clinical data from hospital records, we noticed increased susceptibility to ventricular arrhythmias in affected patients and a history of sudden cardiac deaths (SCDs) in the families. Studies suggested that the patients possessing compound variations in MYBPC3,21,42,43 have shown dosage-dependent effects,42,44–46 therefore, required constant monitoring to avoid adverse outcomes.36,47–49

We studied a few familial samples to understand the co-segregation of variations in families and their association with disease phenotypes. As, the genotype of the patient’s family members are extremely important to understand the genotype-phenotype correlation,23,33,34 and how it might modify the clinical course and prognosis of the disease along with other factors like epigenetics, lifestyle, environment, etc.50–53 We understood from our study that most of the patient’s family members possessing mutations in MYBPC3 gene did not show any symptom when they were below 15 years of age, and they all started having the symptom in their 3rd decade of life, ie, late onset of the disease symptoms. Therefore, we too strongly suggest that the mutations in MYBPC3 showed slightly lower penetrance, delayed onset, and milder forms of disease progression.48,54,55

Studies reported deletions, insertions, and splice site variations in the MYBPC3 gene.56–61 In our previous study on MYBPC3, we observed a founder 25bp del in MYBPC3 of HCM, DCM, and RCM and evaluated its distribution among the South-Asian population, and pinpointed an association with familial cardiomyopathies with an increased chance of heart failure [overall OR, 6.99; p = 4 \times 10 (−11)].23 In the present study, we report 16 missense mutations in the MYBPC3 gene of Indian cardiomyopathy patients and those were absent in 197 normal healthy controls (Table 2 and Figure 1A). Remarkably, we found that 7 out of 16 heterozygous missense mutations in MYBPC3 (V158M, E258K, R272C, A392T, V483A, G522E, and A626V) (Figure 1C) were altering the native evolutionarily conserved amino acids (Figure 1D), accounting for 8.7% and 6.3% in HCM and DCM, respectively. Polyphen-2 or SIFT bioinformatics tools also predicted that those 7 missense mutations were pathogenic (Table 2). The co-segregation of those mutations in families also confirmed their pathogenicity. Except for two missense mutations, R272C and V483A, the remaining 5 missense mutations (V158M, E258K, A392T, G522E, and A626V) were also detected along with other variations in the MYBPC3 gene as compound mutations (Table 4).

In our previous studies, we reported a few genetic variations in other sarcomere genes of Indian cardiomyopathy patients: Tropomysin (α-TMPT),45 Tropontin I3 (TNNI3),24,62 Tropontin T2 (TNNT2),34,63 Actin (ACTC),64 Myosin (β-MYH7),35,65,66 and MYL2 & MYL3.67 Therefore, our present and previous studies clearly illustrated the prevalence and spectrum of variations in sarcomere genes and their associations in Indian population with cardiomyopathies.23,24,34,35,45,62–67

Our categorization as pathogenic variations relied on the result that we could detect those missense mutations exclusively in patients and their family members. In the present study, we found 19 novel SNPs in the MYBPC3 gene, along with accumulated compound variations that were responsible for more severe disease phenotypes in Indian

**Table 4 Compound Mutations in Myosin Binding Protein C (MYBPC3) Gene**

<table>
<thead>
<tr>
<th>S:No</th>
<th>SNP_AA Change</th>
<th>CON</th>
<th>HCM</th>
<th>DCM</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>K244K, E258K, T&gt;G[IVS6+2T]</td>
<td>–</td>
<td>I(HU22)</td>
<td>–</td>
</tr>
<tr>
<td>2</td>
<td>L104M, G522E, A626V</td>
<td>–</td>
<td>I(HU1)</td>
<td>–</td>
</tr>
<tr>
<td>3</td>
<td>P186P, G522E, A626V</td>
<td>–</td>
<td>I(HU28)</td>
<td>–</td>
</tr>
<tr>
<td>4</td>
<td>5'UTR, A392T, E393K</td>
<td>–</td>
<td>–</td>
<td>I(DU79)</td>
</tr>
<tr>
<td>5</td>
<td>V158M, G522E</td>
<td>–</td>
<td>–</td>
<td>I(DU106)</td>
</tr>
<tr>
<td>6</td>
<td>V158M+T262T+A626V</td>
<td>–</td>
<td>–</td>
<td>I(DU99)</td>
</tr>
</tbody>
</table>

**Abbreviations:** SNP, single nucleotide polymorphism; AA, amino acids; CON, controls; HCM, hypertrophic cardiomyopathy; DCM, dilated cardiomyopathy.
cardiomyopathies. Our present comprehensive genetic analysis of the MYBPC3 gene in Indian HCM and DCM patients has given important insight into risk stratification. Based on our present and previous studies on sarcomere genes in Indian population,\textsuperscript{23,24,34,35,45,62–67} we fully agree that the mutations in myosin heavy chain and myosin binding protein C are the frequent causes of cardiomyopathies; therefore, these two genes should be screened first, secondly, the thin filament regulatory genes (TNNT2, TNNI3, and TPM1), and finally, the rarely involved genes like TTN, MYL2, MYL3, and ACTC. Importantly, it is not sufficient and advisable to screen only the known reported mutations, because we could miss unique, rare, and population-specific disease-causing mutations.

**Limitations of the Study**

For any genetic study, it is crucial to extend the study with their family members to understand the inheritance pattern and to correlate the mutations with the disease phenotype. However, generally, it is tough to collect the samples from family member for genetic analysis, mainly because the patients are not strictly adhering to the follow-up procedures that would have allowed us to invite the family members for counselling and further genetic studies. Though we identified missense mutations in many individuals, we could not establish the genotype-to-phenotype correlation within the family in many cases. Thus, for some patients, performing genetic testing, understanding their family history, and giving counselling is not an easy task!

**Conclusion**

The present comprehensive study has revealed both single and compound mutations in MYBPC3 and their association with disease in Indian population with cardiomyopathies. Our findings may perhaps help in initiating diagnostic strategies and eventually recognizing the targets for therapeutic interventions.

**Acknowledgments**

We thank all cardiomyopathy patients both HCM and DCM and their family members and all the healthy volunteers as normal controls, who participated in this study.

**Funding**

Rani DS has been supported by the CSIR-CCMB, Hyderabad, Telangana, India. K Thangaraj has been supported by the JC Bose Fellowship (JCB/2019/000027) from SERB, DST, and The Government of India. However, the funders had no role in designing the study, the collection of data, the analysis of sequence data, the decision to publish, or the preparation of the manuscript.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


Pharmacogenomics and Personalized Medicine

Publish your work in this journal

Pharmacogenomics and Personalized Medicine is an international, peer-reviewed, open access journal characterizing the influence of genotype on pharmacology leading to the development of personalized treatment programs and individualized drug selection for improved safety, efficacy and sustainability. This journal is indexed on the American Chemical Society’s Chemical Abstracts Service (CAS). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/pharmacogenomics-and-personalized-medicine-journal